However, patients who had both FGF/FGFR abnormalities and co-alterations in receptor tyrosine kinases or MAPK or PI3K pathway showed no significant difference in OS when compared to patients with cancers harboring FGF/FGFR pathway alterations without those co-altered pathways (Figure 3C and D). This evidence concerns the gene NTRK1 and cancer.